mRNA vaccine targeting KRAS mutant antigens (Hanmi Pharmaceuticals)

N/A

Report date: 2026/01/26 17:59:10

Base Information

Drug NamemRNA vaccine targeting KRAS mutant antigens (Hanmi Pharmaceuticals)
Drug Alias NamemRNA vaccine (Hanmi Pharmaceuticals)mRNA vaccine encoding KRAS mutant antigens (Hanmi Pharmaceuticals)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A